Search Results: Prevention, Detection & Risk (5 results)
Men at High Genetic Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome
https://www.facingourrisk.org/research-clinical-trials/study/144/atorvastatin-aspirin-for-colorectal-cancer-prevention-for-people-with-lynch-syndrome
Prevention
This study will look at how well atorvastatin (a cholesterol lowering agent) works with or without aspirin in preventing colorectal cancer in people with Lynch syndrome. Atorvastatin may lower the risk of developing cancers in the colon and rectum. Aspirin may reduce the risk of colon polyps and colon cancers. Giving atorvastatin and aspirin may work better at reducing the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.
Blood Markers of Early Pancreas Cancer
https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer
Prevention
Screening for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
The purpose of this study is to try to find markers of early pancreatic cancer for screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.
A Pancreatic Cancer Screening Study for High Risk Individuals
https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people
Prevention
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
Pancreatic Cancer Early Detection Program
https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection
Prevention
This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + lynch syndrome
4 results
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT ID: NCT05129605 (https://ClinicalTrials.gov/show/NCT05129605)
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study
NCT ID: NCT05410977 (https://ClinicalTrials.gov/show/NCT05410977)
Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://ClinicalTrials.gov/show/NCT03568630)
Pancreatic Cancer Early Detection Program
NCT ID: NCT02206360 (https://ClinicalTrials.gov/show/NCT02206360)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.